Winclob-NF Cream is a topical formulation combining Ciprofloxacin (1.0% w/w), Metronidazole (1.0% w/w), Terbinafine (1.0% w/w), and Clobetasol (0.05% w/w), designed for the effective management of mixed bacterial, protozoal, fungal infections, and inflammatory dermatoses. Ciprofloxacin, a broad-spectrum fluoroquinolone antibiotic, targets Gram-positive and Gram-negative bacteria by inhibiting DNA gyrase, thereby preventing bacterial replication. Metronidazole exhibits potent activity against anaerobic bacteria and protozoa by disrupting DNA synthesis. Terbinafine, an allylamine antifungal agent, inhibits squalene epoxidase, leading to ergosterol depletion and fungal cell membrane disruption, effectively treating dermatophytic infections. Clobetasol propionate, a potent corticosteroid, exerts anti-inflammatory, antipruritic, and vasoconstrictive effects, reducing erythema, swelling, and itching associated with inflammatory skin conditions. The synergistic combination in Winclob-NF Cream provides comprehensive treatment for complex dermatological conditions involving mixed infections and inflammation, such as infected eczema, dermatitis, and fungal-bacterial co-infections. It is intended for topical use only and should be applied as directed by a healthcare professional to minimize potential adverse effects, including skin atrophy and systemic absorption. Caution is advised in prolonged use or application on large body areas. Winclob-NF Cream offers an integrated therapeutic approach for multifactorial skin infections and inflammatory disorders.